Results 191 to 200 of about 74,239 (256)
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo +4 more
wiley +1 more source
Scalp Dysesthesia: Emerging Pathophysiologic Insights and Therapeutic Implications
Scalp dysesthesia is a chronic condition diagnosed through exclusion. This scoping review synthesized data from 59 patients to identify recurrent clinical features, comorbidities, and management strategies that may support earlier diagnosis. Emerging patterns suggest that neuronal sensitization may underlie common symptoms.
Aditya K. Gupta +4 more
wiley +1 more source
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden +13 more
wiley +1 more source
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley +15 more
wiley +1 more source
Tissue Resident Memory Cells: Friend or Foe?
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude +2 more
wiley +1 more source
ABSTRACT Aim(s) To explore experiences of chronic hepatitis B (CHB) care among migrant MSM and female sex workers attending a specialist sexual health clinic and identify perceived enablers of person‐centred care. Design Qualitative interview study.
Horas T. H. Wong +8 more
wiley +1 more source
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa +14 more
wiley +1 more source
Male genital lichen sclerosus is driven by chronic, occluded exposure of susceptible genital epithelium to urine, rather than infection or autoimmunity. This review synthesizes clinical, anatomical and molecular evidence showing how microincontinence and occlusion initiate inflammation, fibrosis and carcinogenesis, and explains the curative effect of ...
Georgios Kravvas +3 more
wiley +1 more source
Female genital lichen sclerosus
This review provides a comprehensive overview of clinical presentation and emerging evidence supporting a predominantly immune‐mediated pathogenesis characterized by Th1‐skewed inflammation, epithelial dysfunction and progressive fibrosis. Contributory factors including the emerging role for occlusive exposure of susceptible epithelium to urine are ...
Ashley Spencer, Sandra Jerkovic Gulin
wiley +1 more source
ABSTRACT Background and Aim Risankizumab, a monoclonal interleukin 23p19 antibody, is a treatment for ulcerative colitis. This post hoc analysis reports the efficacy and safety of risankizumab for ulcerative colitis in patients in East Asia from the global phase 3 clinical trials. Methods In the 12‐week, phase 2b/3 induction study (NCT03398148), adults
Ken Takeuchi +14 more
wiley +1 more source

